Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment
复制标题
DOI：
10.1093/cid/ciz074
复制
发表时间：
2019-10-01
影响因子：
11.8
通讯作者：
Kranzer, Katharina
中科院分区：
文献类型：
--
作者：
Polsfuss, Silke;Hofmann-Thiel, Sabine;Kranzer, Katharina
两种新药delamanid和bedaquiline最近被批准用于治疗耐多药和广泛耐药结核病。在这里，我们报告一例氯法齐明，贝达喹啉和低水平德拉曼耐药在治疗期间获得的XDR结核患者。
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.